Riskpilot← Back to searchSign inGet full accessShire Biotech Denmark ApS
APSDissolvedCVR 33358008Havneholmen 29Manufacture of pharmaceutical preparations · NACE 2120Est. 201010 employees
Revenue 2017
DKK 12,7M
+39% vs 2016
EBITDA margin
9.4%
+8% vs 2016
Equity ratio
32.4%
Financial strength
Net profit 2017
DKK 860K
+11% vs 2016
| Revenue | DKK 12,7M | +39% |
| EBITDA | DKK 1,2M | +8% |
| Net profit | DKK 860K | +11% |
| Total assets | DKK 9,9M | +26% |
| Equity | DKK 3,2M | +37% |
| Employees | 10 | — |
Legal name
Shire Biotech Denmark ApS
CVR number
33358008
Legal form
Anpartsselskab
NACE code
2120 · Manufacture of pharmaceutical preparations
Founded
1. december 2010
Share capital
DKK 80.000
Employees
10 (FTE)
VAT registered
No
Audit selected
No
Last report
2017-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af direktøren eller af et bestyrelsesmedlem alene.
Address
Havneholmen 29
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2013 | 2014 | 2015 | 2016 | 2017 |
|---|---|---|---|---|---|
| Revenue | 4.753 | 7.151 | 9.706 | 9.117 | 12.676 |
| Staff expenses | -4.363 | -6.541 | -8.693 | -8.018 | -11.487 |
| EBITDA | 389 | 610 | 1.014 | 1.099 | 1.188 |
| Depreciation & amort. | -13 | -13 | -64 | -69 | -60 |
| EBIT | 377 | 598 | 950 | 1.030 | 1.128 |
| Net financials | -20 | -17 | -31 | -11 | -1 |
| Profit before tax | 356 | 580 | 919 | 1.020 | 1.126 |
| Tax | 124 | 238 | 251 | 244 | 266 |
| Net profit | 232 | 343 | 669 | 776 | 860 |
| Item | 2013 | 2014 | 2015 | 2016 | 2017 |
|---|---|---|---|---|---|
| Total assets | 4.584 | 3.823 | 4.444 | 7.838 | 9.913 |
| Equity | 561 | 903 | 1.572 | 2.347 | 3.208 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 4.024 | 2.920 | 2.873 | 5.490 | 6.705 |
| Total debt | 4.024 | 2.920 | 2.873 | 5.490 | 6.705 |
EBITDA margin
9.4%
This company
15.8%
Market median
-41% vs market
20132017
Equity ratio
32.4%
This company
38.2%
Market median
+15% vs market
20132017
Return on equity
26.8%
This company
18.4%
Market median
+46% vs market
20132017
Net profit margin
6.8%
This company
8.1%
Market median
-16% vs market
20132017
Asset turnover
1.28×
This company
1.12×
Market median
+14% vs market
20132017
Debt / equity
2.09×
This company
0.62×
Market median
-237% vs market
20132017
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via CVR / Virk · Period 2013-01-01 – 2013-12-31
| Name | Role | Member since |
|---|---|---|
| Former (6) | ||
JE Management | Management | 2013 – 2015 |
PM Management | Management | 2015 – 2017 |
LE Management | Management | 2010 – 2012 |
PA Management | Management | 2010 – 2010 |
KA Chief Executive Officer | Chief Executive Officer | 2017 – 2018 |
MC Management | Management | 2012 – 2013 |
| Name | Role | Member since |
|---|---|---|
| Former (7) | ||
| Board of Directors | 2017 – 2018 | |
| Board of Directors | 2017 – 2018 | |
| Board of Directors | 2015 – 2016 | |
| Board of Directors | 2010 – 2014 | |
| Board of Directors | 2010 – 2017 | |
| Board of Directors | 2016 – 2017 | |
| Board of Directors | 2014 – 2015 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2018 | |
| Individual | 100% | 100% | 2010 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Shire Biotech Denmark ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| John Erik Mattias Bankel | Management | 0 companies |
| Paul Michael Blanchfield | Management | 0 companies |
| Lars Eric Jernestahl | Management | 0 companies |
| Peter Andreas Stakemann | Management | 0 companies |
| Kerstin Anna-Lena Engvall | Chief Executive Officer | 0 companies |
| Mary Christine Di Marzio | Management | 0 companies |
| Johan Åke Östen Pettersson | Board of Directors | 0 companies |
| Jacob Fredrik Westin | Board of Directors | 0 companies |
| Jasper Sökeland | Board of Directors | 0 companies |
| Michael Thomas Garry | Board of Directors | 0 companies |
| Helen Alice Lillistone | Board of Directors | 0 companies |
| Amanda Miller | Board of Directors | 0 companies |
| Helen Rosemary Janaway | Board of Directors | 0 companies |